Menu
Recruiting NCT03966014

Different Amoxicillin Treatment Regimens in Erythema Migrans Patients

Phase III Interventional Erythema Migrans

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: EM-amoxicillin 3 x 10 days, EM-amoxicillin 3 x 14 days, Controls.
Who it may be relevant to
Registry conditions: Erythema Migrans. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Slovenia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Different Duration and Dosing of Amoxicillin in Patients With Erythema Migrans. A Randomized Clinical Trial.

Overview

The purpose of this study is to compare the efficacy of different amoxicilline treatment regimens in patients with erythema migrans.

Interventions

  • Drug EM-amoxicillin 3 x 10 days
    Patients will receive amoxicillin 500 milligram tid for 10 days
  • Drug EM-amoxicillin 3 x 14 days
    Patients will receive amoxicillin 500 milligram tid for 14 days
  • Other Controls
    No intervention.

Primary outcome measures

  • Number (frequency) of patients with objective manifestations of Lyme borreliosis or subjective Lyme borreliosis-associated/post-Lyme borreliosis symptoms [Time frame: One year follow-up]
Secondary outcome measures (1)
  • Number (frequency) of patients with nonspecific symptoms [Time frame: One year follow-up]

Eligibility criteria

Inclusion criteria

  • erythema migrans

Exclusion criteria

  • pregnancy
  • extracutaneous manifestations of Lyme borreliosis
  • immunocompromising state
  • serious adverse event to beta lactam antibiotic
  • receiving antibiotic with antiborrelial activity within 10 days

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Slovenia · 2 centers
  • University Medical Centre Ljubljana — Ljubljana
  • University Medical Centre Ljubljana — Ljubljana

Identifiers

NCT: NCT03966014 · Amoxy 10-14

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗